Login to Your Account

Wilex Shares Plunge; Rencarex Disappoints in Phase III Study

By Cormac Sheridan
Staff Writer

Tuesday, October 16, 2012
Shares in Wilex AG plunged 60 percent just before the markets closed in Frankfurt, Germany, Tuesday, on news that a protracted Phase III trial of Rencarex (girentuximab) failed to meet the primary endpoint of disease-free survival in patients with clear cell renal carcinoma (ccRCC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription